Home Health J&J Is Focused on Fighting Cancer, Not Obesity Drugs, CEO Says
Health

J&J Is Focused on Fighting Cancer, Not Obesity Drugs, CEO Says

J&J Is Focused on Fighting Cancer, Not Obesity Drugs, CEO Says
Key Points

Jun 17th, 2026 J&J Is Focused on Fighting Cancer, Not Obesity Drugs, CEO Says Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo...

Jun 17th, 2026 J&J Is Focused on Fighting Cancer, Not Obesity Drugs, CEO Says Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk. [Image text:] MASMINGTON DC Bloomberg ONOMIC CLUB Bloomberg THEEO aC nberg MINGTOK OC OFWAS Bloombe ECONOMIC CLUB serg D.C. David The Rubenstein Show
J&J (PERSON) Johnson & Johnson (ORG) Joaquin Duato (PERSON) Eli Lilly & Co. (ORG) Novo Nordisk (ORG)
Originally published by Bloomberg Markets Read original →